英文药名：G-LASTA Subcutaneous Injection（Pegfilgrastim(Genetical recombination)）

中文药名：基因重组培非格司亭注射剂

生产厂家：协和发酵麒麟

ジーラスタ皮下注3.6mg

治疗类别名称
持续的G-CSF制剂
欧文商標名
G-LASTA Subcutaneous Injection
一般名
ペグフィルグラスチム（遺伝子組換え）
Pegfilgrastim (Genetical Recombination)
分子量
約40,000
本質
甲氧基聚乙二醇（分子量约20,000）修饰蛋白分子结合的氨基非格司亭的MET1（重组）。
操作注意事项
1.请活塞杆的不讲理的操作。此外逆止器，则不会被删除，直到给药结束后。
2.不要从枕头收拾尽可能在使用之前取下注射器。
3.注射器尖端的电影尖帽了，或者说你不使用时发现异常现象，如注射器破裂的。
适应病症
抑制由癌症化疗发热性中性粒细胞减少的发病
用法用量
通常情况下，成人的癌症化疗剂施用后，作为培非司亭（基因重组），化疗1的施用每个周期皮下3.6mg一次第二天结束。
药效药理
1. 药理作用
(1) 中性粒细胞前体细胞分化的促进作用
在体外集落形成测定法中，通过在本药物的存在下，从人培养CD34阳性细胞和小鼠骨髓细胞，嗜中性粒细胞祖细胞的分化促进。
(2) 在中性粒细胞减少的影响
通过给予剂环磷酰胺给药引起外周血中性粒细胞减少鼠标，中性粒细胞减少抑制。
1. 作用机序
这种药物结合到G-CSF受体存在于骨髓中的嗜中性粒细胞祖细胞，促进从嗜中性粒细胞祖细胞分化成嗜中性粒细胞，增加外周血中嗜中性粒细胞计数据推断。
包装规格
皮下：3.6mg  1注射器

制造厂商
协和发酵麒麟有限公司
G-LASTA Subcutaneous Injection（Pegfilgrastim[Genetical recombination]）
G-LASTA Subcutaneous Injection 3.6mg（ジーラスタ皮下注3.6mg） 
Brand name : G-LASTA Subcutaneous Injection 3.6mg
　Active ingredient: Pegfilgrastim (Genetical recombination)
　Dosage form: injection
　Print on wrapping: 
Effects of this medicine
This medicine increases leukocytes (neutrophils) which play an important role for protection against infection.
It is usually used for treat leukopenia (neutropenia) attributed to anticancer agents.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have previously experienced rash or itch after administrating any other drugs which increases leukocytes (neutrophils).
If you are a patient with myeloid leukemia (including myelodysplastic syndrome) and decrease of leukemic cells in the bone marrow is insufficient or leukemic cells are found in the blood.
If you have been administered an anticancer agent within 24 hours.
•If you are pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•In general, this medicine is administered subcutaneously once per chemotherapy course, on or after the next day of treatment completion with anticancer agent.
•Duration of administration will be determined by monitoring the effects. Ask your doctor about the duration of administration.
Precautions while taking this medicine
• Possible adverse reactions to this medicine
The most commonly reported adverse reactions include back pain, fever, arthralgia, malaise, headache, muscle pain and rash. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•chilliness, palpitation, cold sweat, grow pale [shock, anaphylaxis]
•fever, dry cough, difficult to breathe [interstitial lung disease]
•hard to breathe, rapid breathing, lips turn blue, nails and toenails turn blue [acute respiratory distress syndrome]
•shortness of breath, fever, general malaise, easy to bleed, dizziness [increase of blasts]
•left upper quadrant pain, shoulder pain, abdominal bloating [splenomegaly, splenic rupture]
•hypotension, edema, rapid weight increase [capillary leak syndrome]
•fever, raised red rash with pain [Sweet's syndrome]
•fever, bruise, blood blister [cutaneous vasculitis]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Kyowa Hakko Kirin Co.,LtdInjection
Published: 11/2014
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
http://www.info.pmda.go.jp/go/pack/3399410G1020_1_03/